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WBP2 is a WW domain binding protein. It was identified as a nuclear cofactor that 
associates with estrogen receptor and progesterone receptor and mediates the 
transcriptional activation function of these receptors. We have previously shown that 
WBP2 was tyrosine phosphorylated following EGF stimulation. In this study, we 
characterized the phosphorylation kinetics of WBP2 in an endogenous system and 
identified the phosphorylation sites. By creating MCF7 cells stably expressing WBP2, 
its phospho-mimic and phospho-defective mutants, we found that phosphorylation of 
WBP2 leads to increased cancer cell proliferation, even in the absence of hormones. 
To understand the mechanism behind WBP2’s effect in conferring hormone 
independence to cancer cells, we conducted luciferase pathway reporters screening. 
We identified the E2F pathway as one of the pathways activated by WBP2. Protein 
levels of G1/S cell cycle regulator E2Fs were elevated in cells expressing phospho-
mimic WBP2 along with increased DNA synthesis. By RNA interference of E2F1 and 
E2F3, we found that cell proliferation of phospho-mimic WBP2 stable cell line was 
more dependent on E2F compared to cells expressing vector control. Our results 
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1.1 Signal transduction in the cell 
In the multicellular organism, cells do not exist in isolation. Cells need to 
communicate with one another to coordinate growth, differentiation and metabolism. 
The mechanism of communication may occur through direct cell-cell contact or 
through signaling molecules over long distances. These signaling molecules can 
include small molecules, peptides and proteins, and are transported through the 
cellular fluid. They are synthesized by signaling cells, and produce a response in cells 
that have receptors for the signaling molecules. Signal transduction is the process of 
converting these extracellular signals into cellular responses (Alberts 2002). One of 
the main mechanisms of signal transduction is the binding of signaling ligands to 
receptor tyrosine kinases. 
1.1.1 Receptor tyrosine kinases 
Tyrosine kinases are enzymes which carry out phosphorylation on tyrosine residues. 
Tyrosine kinases can be divided into receptor and non-receptor tyrosine kinases. 
Receptor tyrosine kinases are found on cell surfaces, while non-receptor tyrosine 
kinases are found in the cytosol. Examples of receptor tyrosine kinases include 
epidermal growth factor receptor (EGFR) and fibrobast growth factor receptor 
(FGFR) while non-receptor tyrosine kinases include the Src and c-Abl tyrosine 
kinases (Yarden and Sliwkowski 2001) 
 
Upon ligand binding, receptor tyrosine kinases becomes autophosphorylated in their 
cytosolic regions and phosphorylate their substrate proteins. Tyrosine phosphorylation 
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of the kinases lead to signaling cascades, which eventually results in the transcription 
of specific genes (Yarden and Sliwkowski 2001). Overall, the primary function of 
tyrosine kinases is to integrate external signals with the various internal signal 
transduction pathways and activate gene transcription within the cells, allowing the 
cell to respond to the extracellular stimuli (Kholodenko 2006). 
Tyrosine kinases have long been associated with cancer. Of the 100 tyrosine kinases 
identified so far, about 50% have been implicated in human cancers as a result of 
aberrations such as deletion, translocation and overexpression (Lim 2005). These 
aberrations may result in changes in the activity of the tyrosine kinases, leading to 
deregulated phosphorylation of target proteins. Constitutive activation of tyrosine 
kinases can lead to abnormal cell proliferation, and growth, a situation commonly 
observed in cancer (Blume-Jensen and Hunter 2001). One of the better studied 
tyrosine kinases associated with cancer is the epidermal growth factor receptor, or 
EGFR. 
1.1.2 EGFR 
EGFR (epidermal growth factor receptor) is a member of the HER/ERBb family of 
transmembrane receptor tyrosine kinases, which includes HER2, HER3 and HER4 
(Britsch 2007). EGFR is composed of an extracellular ligand binding domain and a 
cytoplasmic carboxy terminal tyrosine kinase (Normanno et al 2006). Ligands that 
bind to EGFR are known as EGF (epidermal growth factor) related peptide factors. 
They include growth factors such as EGF, amphiregulin (AR) and transforming 
growth factor-α (TGF-α) (Yarden and Sliwkowski 2001). Binding of ligands, 
including EGF and TGF-α to the extracellular domain of EGFR results in the 
formation of homodimers and heterodimers with other HER family members and the 
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activation of tyrosine kinase activity (Yarden and Sliwkowski 2001). Receptor 
activation leads to autophosphorylation of tyrosine residues located within the 
cytoplasmic COOH terminal domain and the subsequent recruitment to these sites of 
adaptor proteins that are involved in signal transduction, such as Grb2, Shc, SHP1 and 
Abl. These proteins mainly bind to the tyrosine phosphorylated residues on EGFR 
through their SH2 or PTB domains. These subsequently lead to activation of various 
cytoplasmic effector proteins, including ERK1/2, PI3K and Stat proteins (Yarden and 
Sliwkowski 2001). These effector proteins mediate the activation of signaling 
pathways through regulation of the activities of downstream transcription factors such 
as Akt, or activation of downstream protein kinases such as the MAPK and ERK. The 
EGF signaling network is extensive, and many cellular proteins are phosphorylated 
upon EGFR activation. In one study, following stimulation of EGF in HeLa cells, 
more than 6600 tyrosine phosphorylation sites were detected on 2244 proteins (Olsen 
et al 2006). Ultimately EGFR signaling contributes to the regulation of cellular 
processes such as cell proliferation, survival, adhesion and migration (Yarden and 
Sliwkowski 2001).   
There have been extensive studies done on EGFR, including the characterization of 
the protein and its functional roles in the regulation of important cellular processes 
such as cell growth and differentiation (Yarden and Sliwkowski 2001). In cancer, the 
level of EGFR is frequently elevated due to overexpression (Normanno, De Luca et 
al. 2006). A high level of receptors increases the sensitivity of the tumor cells to low 
concentrations of growth factors. Cancer cells may also overexpress the growth 
factors that bind to EGFR, leading to uncontrolled proliferation, as the cells are able 
to generate their own growth signals. In addition, in cancer, the EGFR protein is often 
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found to be constitutively active due to mutations in cancer, thus leading to 
uncontrolled cell growth (Normanno et al 2006). 
 
Tyrosine phosphorylation functions as a switch that controls cellular signaling. 
Phosphorylation through addition of phosphate group to an amino acid can turn the 
hydrophobic region of the protein into a polar region. Through this mechanism, 
tyrosine phosphorylation could control proteins through regulation of stability, 
protein-protein interactions, subcellular localization and levels of activity (Alberts 
2002) . EGFR signaling leads to MAPK, AKT and JNK signaling pathways 
activation, which results in induction of gene expression programs that mediate 
cellular proliferation and growth (Blume-Jensen and Hunter 2001). Besides these 
pathways, EGFR also crosstalks with estrogen receptor, which belongs to a class of 
transcription factors known as nuclear receptors. In the following section, the 





Figure 1.1: Diagram of pathways downstream of EGFR. Adapted from (Nyati et al 
2006). 
 
1.2   Nuclear receptors 
1.2.1   Classification of nuclear receptors 
Nuclear receptors play a central role in the body’s ability to transduce steroid, thyroid 
and other lipophilic hormones (Tsai and O'Malley 1994). The nuclear receptors 
constitute a large super family of structurally related transcription factors. By their 
nature, steroid, thyroid and lipophilic hormones are able to traverse the plasma 
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membrane and  nuclear membrane (Alberts 2002). Therefore, they are able to contact 
the nuclear receptors either in the cytoplasm or nucleus.  
Nuclear receptors bind to specific DNA sequences termed as nuclear receptor 
response element. These response elements are usually palindromic in nature. 
Accordingly, nuclear receptors bind to DNA response elements as symmetrical dimers 
(Novac and Heinzel 2004) 
The first subclass of nuclear receptors, the steroid receptors, are receptors that are 
primarily activated by steroids, and only bind to their target response elements upon 
ligand stimulation. Examples include the estrogen receptor (ER), androgen receptors 
(AR) and the progesterone receptor (Novac and Heinzel 2004). 
A second subclass is a group of receptors that in the absence of ligand, function to 
repress transcription. They are constitutively bound to DNA and upon stimulation 
with ligands, become potent transactivators. Examples include the thyroid hormone 
receptor (TR) and the retinoic acid receptors (RA) (Novac and Heinzel 2004). 
The third subclass consists of receptors activated by metabolic intermediates such as 
fatty acids, bile acids and sterols. These are called metabolic sensors, and they include 
the peroxisome proliferator activated receptor (PPAR), the liver X receptor (LXR), 
the farnesol X receptor (FXR), and the hepatocyte nuclear factor 4 (HNF4) (Novac 
and Heinzel 2004). 
Nuclear receptors regulate a variety of important biological processes, including 
cellular growth, and organogenesis (Novac and Heinzel 2004). Like other 
transcription factors, nuclear receptor activity is regulated through changes in their 
levels, and post-translational modifications (Rochette-Egly 2003). One of the most 
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prominent modifications for nuclear receptors is phosphorylation events elicited by 
receptor kinases and cytoplasmic kinases, which occurs in the crosstalk between 
EGFR and ER. 
1.2.2  Estrogen receptor  
Estrogen receptors are steroid receptors which respond to estrogens. Binding of 
estradiol to estrogen receptor changes its conformation, and leads to its activation 
(Stanford et al 1986). Estrogen responsive elements are found throughout the 
promoters of many genes in the cell, allowing for estrogen mediated regulation of 
gene transcription of many important cellular proteins (Klinge 2001). Estrogen 
receptor also cooperates with various transcription factors to regulate gene 
transcription (Cicatiello et al 2010).  
Estrogen receptors are divided into two different forms: the estrogen receptor alpha 
(ERα) and estrogen receptor beta (ERβ). ERα is implicated in multiple cancers and is 
overexpressed in a majority of breast cancer cases, referred to as "ER-positive". 
Binding of estrogen to ERα stimulates proliferation of mammary cells (Stanford et al 
1986). 
There has been evidence that EGFR crosstalks with ERα. EGF stimulation could lead 
to phosphorylation and activation of nuclear ERα (Kato et al 1995). This mainly 
occurs through the ability of ERK, which is a downstream kinase of EGFR, to 
phosphorylate serine-118 in the A/B domain of the ERα. Serine-118 phosphorylation 
results in increased ER related transactivation of genes that are upregulated by EGFR. 
It has been shown that phosphorylation of ER leads to more efficient recruitment of 
ER coactivators, and the associated chromatin remodelers (Kato et al 1995). 
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Conversely, estrogen stimulation also leads to transactivation of EGFR, leading to 
cAMP and ERK upregulation (Filardo et al 2000) .  
 
Besides facilitating the phosphorylation of the estrogen receptor, EGFR also regulates 
estrogen receptor related signaling through the regulation of nuclear receptor 
coactivators. Through this mechanism, both components contribute to the formation 
of an efficient transcription  initiation complex and a controlled enhancement of the 
response to the ligand (Wu et al 2005). 
 
1.3  Nuclear receptor coregulators  
1.3.1   Discovery of nuclear receptor coregulators 
Nuclear receptor co-regulators are proteins which modulate the function of nuclear 
receptors. They were first discovered after experiments in yeasts indicating  that in 
addition to core polymerase proteins, an additional set of helper proteins assists in 
communication between transcription factors and the polymerase II complex (Lonard 
and O'Malley 2005).  
When co-regulators were first discovered, it was thought that they were common 
components of the transcriptional machinery and not more than ten would be found. 
Today, hundreds of co-regulators have been discovered through increasingly 
advanced technologies such as chromatin immunoprecipitation, microarray and 
bioinformatics. Based on the amino acid sequences, these co-regulators are highly 




1.3.2   Classification of nuclear receptor coregulators 
Nuclear receptor co-regulators can be classified into two types, nuclear receptor co-
activators, and nuclear receptor co-repressors. Nuclear receptor co-activators are 
molecules that are recruited by nuclear receptors to enhance transcription while co-
repressors function to suppress transcription (O'Malley 2007). Nuclear receptor 
coactivators generally bind to nuclear receptors only upon the ligand stimulation of 
the nuclear receptor. In contrast to coactivators, corepressors repress gene expression 
by interacting with unoccupied nuclear receptors (Glass and Rosenfeld 2000). 
Nuclear receptor coativators can be further divided into two groups, the primary 
coactivators and the secondary coactivators (Stallcup et al 2003). The primary 
coactivators can contact the nuclear receptor through direct binding while the 
secondary coactivators are part of the complex which also contribute to the 
enhancement of NR mediated transcription without directly contacting the nuclear 
receptor (McKenna et al 1999). Primary coactivators play a major role in modulating 
the multicomponent complex. They have enzymatic activities which allows them to 
enzymatically target the other components of the complex. They also have protein 
binding domains which recruit components, such as other co-regulators, or the basal 
transcriptional machinery (Stallcup, Kim et al. 2003). 
 
1.3.3  Function of nuclear receptor coregulators 
An emerging theme over the past few years has been the growing importance of 
nuclear receptor coregulators as a master regulator in regulating transcription. 
Coregulators are usually a part of a multi-component protein complex (Jung et al 
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2005). These complexes are dynamically arranged depending on the role of the 
complex and the stages of transcription (Wu et al 2006, Wu et al 2005). As part of a 
multi subunit complex, coregulator complexes can have multiple enzymatic activities, 
including  kinases, methylases, acetyltransferases, deacetylases and ubiquitins. As 
coregulators control a large complex that supplies a variety of enzymatic activities, 
they are able to exert a broad effect on transcription (Jung et al 2005). 
Nuclear receptor co-regulators play a diverse role in the cell. Among others, they 
function to integrate signals from the extracellular environment into appropriate 
signaling pathways and gene expression in the cell. They function prominently in 
crosstalking between signaling pathways, as a coregulator can often be the target of 
multiple signaling pathways. As an example. the histone acetyltransferase activity of 
CREB binding protein (CBP) could be regulated by cyclin-dependent kinases, leading 
to modulation of its activitiy during the cell cycle (Ait-Si-Ali et al 1998). CBP 
coactivation of CREB is enhanced in response to calcium signaling via a mechanism 
involving calmodulin kinase IV (Chawla et al 1998). In many cases, nuclear receptor 
coactivators also modulate the activity of multiple transcription factors, allowing 
coordination between cellular processes. For example, the SRC-3 coactivator is able 
to coactivate a wide variety of transcription factors, such as ER (Shao et al 2004), 
nuclear factor-κB (NF-κB) (Na et al 1998), activator protein 1 (AP-1) (Lee et al 
1998), and E2F1 (Louie et al 2004). 
 
1.3.4  Regulation of nuclear receptor coregulators 
Co-regulators levels are tightly controlled in response to the environment. Their 
protein levels change due to modulation in the protein expression of the co-regulators 
themselves. The cellular levels of coactivators are also frequently regulated by 
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altering their post-translational degradation rates. A high cellular concentration of a 
co-activator will lead to amplification of the downstream pathway and also a more 
rapid response to environmental signals (O'Malley and Kumar 2009). 
In addition, co-regulators are regulated through post-translational modifications 
(PTM) such as phosphorylation, methylation, acetylation, and sumoylation (Lonard 
and O'Malley 2005). Each PTM can offer a different functional outcome, for example 
polyubiquitination can signal for destruction, while phosphorylation signals for 
activation. Since co-regulators PTMs can occur on different amino acid sites 
throughout the protein, each co-regulator can undergo modification for a broad 
spectrum of activity (O'Malley et al 2008). For example, the regulation of SRC-3 by a 
variety of post-translational modification provides for multiple functional outcomes. 
Some of the modifications undergone by Src-3 include sumoylation, phosphorylation, 
and ubiquitination (Wu et al 2006, Wu et al 2004, Wu et al 2007).  
Phosphorylation of SRC-3 has also been shown to selectively affect its interactions 
with other proteins (Wu et al 2004). Distinct patterns of SRC-3 phosphorylation can 
change the specificity of SRC-3 for different transcription factors. For example, six 
phosphorylation sites on SRC-3 could be phosphorylated in response to stimulation 
from EGF, steroid hormones and cytokines, and increased intracellular cAMP and the 
combination of phosphorylation events allows pathways to be activated selectively 
(Font de Mora and Brown 2000, Wu et al 2004). A combination of phosphorylation 
events at specific sites on SRC-3 allows the coactivator to selectively activate 







Figure 1.2 Regulation of SRC family of transcription coactivators by post 
translational modifications. The SRC family of transcription coactivators are 
regulated by various post translational modifications such as sumoylations, 
ubiquitination, methylation, acetylations and phosphorylations. These modifications 
result in modulation of SRC activities and their stabilization or degradation. Adapted 
from (Xu et al 2009). 
 
 
Post –translational modifications of the co-regulators can give the cell more control 
over gene expression compared  to post-translational modification of the target of the 
co-regulators. For comparison, modification of histone usually affects only the 
expression of individual genes, but the post translational modification of coregulators 
can regulate a substantial number of genes, leading to broad changes in cell processes 




1.3.5   Nuclear receptor coregulators in diseases 
Nuclear receptor co-regulators regulate the expression of genes involved in diverse 
cellular functions. As such, they also have the potential to cause cellular pathologies 
associated with aberrant gene expression. Of the 300 coregulators identified by 
August 2007,  more than 165 of them already had been associated with some disease 
state in humans (O'Malley 2006). This observation shows that co-regulators are highly 
correlated with disease states, and therefore may constitute an important class of 
therapeutic targets (O'Malley and Kumar 2009).  
 
Many instances of coregulator expression in human cancer tissues have been 
published (Lonard et al 2007). Overall, more nuclear receptor coregulators are 
overexpressed rather than underexpressed  in cancers (Lonard et al 2007). 
Misexpression of key regulatory factors that integrate functional signaling networks in 
a cancer cell can lead to diseases, and limit treatment options of therapeutic drugs 
(O'Malley and Kumar 2009). 
 
1.4  WBP2  
WBP2 or WW domain Binding Protein 2 is a ubiquitously expressed 38 kDa protein. 
It is one of the two isoforms of WBP, the other of which is WBP1. WBP2 was first 
discovered as a protein that binds to the WW domain of YAP (Yes-associated Protein) 
(Sudol et al 1995). Besides binding to YAP, WBP2 has also been found to interact 
with Pax8 (Nitsch et al 2004), and estrogen receptor and progesterone receptor 
(Dhananjayan et al 2006).  
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1.4.1   Domains of WBP2 
WBP2 contains a GRAM domain and 3 PPXY motifs embedded within a polyproline 





Figure 1.3 Schematic diagram of WBP2 domains.Diagram shows the domains in 
WBP2. WBP2 contains a GRAM domain on the N-terminus, and a polyproline rich 
motif on the C-terminus. 
 
 
1.4.1.1  GRAM domain 
WBP2 contains a GRAM domain on its N-terminus. The GRAM domain can be 
found in glucosyltransferases, myotubularins and other membrane-associated proteins 
(Doerks et al 2000). The structure of the GRAM domain is similar to PH domains 
(Begley et al 2003). No function has thus far been attributed to the GRAM domain of 
WBP2.  
1.4.1.2  PPXY motifs 
WBP2 contains 3 PPXY motifs in its C-terminus region. The PPXY motif is a proline 
rich motif that binds to WW domains. It represents the largest class of WW domain 
ligands (Macias et al 2000). The PPXYs motif on WBP2 allows it to interact with the 
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WW domain of YAP (Sudol et al 1995). It is speculated that the presence of the 
PPXY motif within transcription factors may recruit WW domain-containing proteins 
such as YAP, which has been known to act as transcriptional coactivators (Yagi et al 
1999). YAP has been found to interact with some of the PPXY motifs containing 
transcription factors such as the ErbB4 intracellular domain (Komuro et al 2003), 
Runx2 (Yagi et al 1999), and p73 (Basu et al 2003).  
 
1.4.2   Function of WBP2 
1.4.2.1  Function of WBP2 as a coactivator 
WBP2 has been demonstrated as a transcriptional coactivator for estrogen receptor 
and progesterone receptor (Dhananjayan et al 2006). In the paper, WBP2 was found to 
be an interacting protein of E6-AP, which is itself a dual-function steroid hormone 
receptor coactivator (Nawaz et al 1999). WBP2 interacts with estrogen receptor and 
progesterone receptors in a hormone dependent manner and is able to modulate their 
transactivation. Chromatin immunoprecipitation assays have demonstrated that WBP2 
is recruited to estrogen-responsive promoter (Dhananjayan et al 2006). Mutational 
analysis suggests that the third PY motif of WBP-2 is essential for its coactivation and 
intrinsic activation functions. It was shown that WBP-2 and E6-associated protein 
each enhanced PR function, and their effect on PR action are additive when 
coexpressed, suggesting a common signaling pathway. Yes kinase-associated protein 
(YAP), which interacts with WBP2, is able to enhance PR transactivation, but YAP's 
coactivation function is absolutely dependent on WBP-2. Thus, WBP2 is shown to be 




1.4.2.2  Function of WBP2 as an adaptor 
WBP2 has been found to interact with Pax8 (Nitsch et al 2004). The interaction was 
verified by in vitro biochemical association assays and by in vivo co-
immunoprecipitation. Pax proteins are key regulators during the organogenesis of 
various tissues (Mansouri et al 1996) and are crucial for the maintenance of a thyroid 
differentiated phenotype and transcriptional activation for all the thyroid 
differentiation markers (Pasca di Magliano et al 2000). However, when WBP2 and 
Pax8 was coexpressed in HeLa cells, no effect on Pax8 transcriptional activity was 
observed. WBP2 may function as an adaptor protein but not as a coactivator protein 
for Pax8 (Nitsch et al 2004). 
 
1.5  The cell cycle  
The cell cycle is a series of events that culminate in the division of a cell into two 
daughter cells. In eukaryotic cells, the cell cycle can be divided into the interphase and 
the mitosis phase. During the interphase phase, cells accumulate nutrients and duplicate its 
DNA and during mitosis, the cells split itself into two daughter cells. Cells that have 
temporarily stopped or reversibly stopped dividing are said to have entered a state of 
quiescence called G0 phase (Alberts 2002). 
1.5.1   Cell cycle phases 
During the G1 phase, the cell begins to synthesize many of the components needed for 
DNA synthesis and the subsequent mitosis (Alberts 2002). Entry into G1 is dependent 
on cell type and context. For example, intestinal stem cells, lymphocytes and 
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angioblasts all proceed through G1 phase under different circumstances, signals, and 
timings (Massague 2004). 
Following the G1 phase, the cells begin to synthesize DNA during the S-phase. The 
existing DNA is replicated so that the chromosome is duplicated into two sister 
chromatid  (Alberts 2002). Entry into S phase is preceded by activation of the cyclin 
dependent kinases (Massague 2004). Cyclin dependent kinases (CDK) are protein 
kinases that require binding to cyclins to become catalytically competent. Different 
members of CDK family associate with different cyclins throughout the cell cycle 
(Murray 2004). 
G1 CDKs, which include Cdk2, combine with the cyclin E and cyclin A to trigger 
entry into the S phase. On activation of Cdk2, DNA replication ensues (Morgan 
1997). In normal cells, Cdk2 is kept inactive until mitogenic signals intervene.  
1.5.2   The E2F family of proteins 
The E2F family of transcription factors function downstream of the retinoblastoma 
pathway and play an important role in cell division control (Dimova and Dyson 
2005). 
1.5.2.1  Members of the E2F family of proteins 
E2F proteins are subdivided into two groups based on their transcriptional properties 
and interaction with the three RB-related pocket proteins (RB, p107 and p130) 
(Dimova and Dyson 2005). E2F1, E2F2 and E2F3 are transcriptional coactivators. 
They interact exclusively with the RB proteins. In contrast, E2F4 and E2F5 are appear 
to function as repressors by recruiting pocket proteins to E2F regulated promoters. 
E2F4 is able to interact with all three pocket proteins, while E2F5 is able to bind to 
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p130 only (Beijersbergen et al 1994, Hijmans et al 1995). Several other E2Fs such as 
E2F6, E2F7 and E2F8 have been discovered in recent years, and their functions are 
less clear (Dimova and Dyson 2005). 
 
Figure 1.4 The mammalian E2F/RB network. Activator E2Fs E2F1, E2F2 and 
E2F3  interact only with pRB; E2F4 can interact with all three pocket proteins, E2F5 
binds to p130, E2F6 binds to PcG proteins E2F6 and E2F7 do not interact with pocket 
proteins. Adapted from (Dimova and Dyson 2005). 
 
1.5.2.2  Mechanism of action of E2F family proteins 
The biological activities of E2F are controlled by the binding of pocket proteins. 
Binding of pocket proteins can directly inhibit the ability of activator E2F to initiate 
transcription (Dimova and Dyson 2005). The other mechanism is when repressor 
E2Fs such as E2F4 and E2F5 recruit RB related proteins to E2F regulated promoters 
(Frolov and Dyson 2004). 
In resting cells, E2F proteins are bound to Rb proteins or its family members, and are 
inactive(Lipinski and Jacks 1999). Upon mitogenic stimuli, D type cyclins are 
increased, which combine with Cdk4 and Cdk6 to phosphorylate and inactivate Rb. 
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The phosphorylation dissociates Rb from E2F, allowing E2F dependent transcription 
(Sherr and Roberts 1999). E2F dependent transcription leads to the transcription of 
genes such as cyclin E and cyclin A.  Along with these, E2Fs activate transcription of 
a large set of components that support DNA replication (Sears and Nevins 2002). 
Increased  levels of cyclin E activates Cdk2 during G1, which can also phosphorylate 
Rb, creating a positive feedback loop that helps to precipitate S phase entry. 
The number of genes and nature of genes regulated by the E2F transcription factor 
have enlarged considerably in recent years with the application of new technology 
such as DNA microarray analysis, chromatin immunoprecipitation and bioinformatics 
(Bieda et al 2006, Bracken et al 2004, Iwanaga et al 2006). E2F target genes have 
ranged from traditional set of G1/S regulators to genes with other cell cycle functions, 
DNA repair and recombination, apoptosis, differentiation and development as well as 
genes with unknown functions (Dimova and Dyson 2005). Based on the discoveries 
of these new genes, E2F proteins are now also implicated in many other cellular 
functions. Thus, the traditional view of E2F proteins as regulator of cell cycle may be 
too simplistic. E2F proteins have also been implicated in regulation of apoptosis, 
DNA repair and DNA damage checkpoint control, regulation of mitosis, direct 
regulation of DNA replication, differentiation and in tumor development as well as 
tumor suppression (Dimova and Dyson 2005). 
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Figure 1.5 Current molecular model for E2F/RB function. E2F4 or E2F5 
complexes are present at cell cycle-regulated promoters in quescient and function to 
repress transcription. Upon mitogenic stimulation G1, Cdks phosphorylate pocket 
proteins and disrupt E2F/pocket protein interactions. In late G1 and early S phase, 
activator E2Fs (E2F1−3) bind to cell cycle-regulated promoters and activate 
transcription. Cell cycle exit and differentiation signals block this transition. Adapted 
from (Dimova and Dyson 2005). 
 
1.5.2.3  Function of E2F proteins in S phase entry 
One of the most prominent functions of the E2F protein is its ability to induce S-phase 
(Dyson 1998). This property is central to most models of E2F function and was first 
shown for E2F1 (Johnson et al 1993). Subsequently this has also been shown to be 
true for E2F2 and E2F3 (Lukas et al 1996). The repressor E2Fs also play a role in 
controlling S-phase entry. The repressor complex is more prevalent in G0 and early 
G1phase. Stimulation of the cells lead to disruption of the repressor complex through 
phosphorylation by G1 CDKs (Nevins 1998).  
 
This model is further substantiated by the finding that cells lacking the repressors 
E2F4 and E2F5, fail to respond to cell cycle arrest signals and therefore play a role in 
cell cycle exit and differentiation. (Gaubatz et al 2000). 
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The importance of activators E2Fs in S phase entry is highlighted by the fact that 
overexpression of activator E2Fs can drive cells into S phase (DeGregori et al 1997, 
Shan and Lee 1994). The activator E2Fs can also overcome growth arrest signals 
resulting from TGF beta and CDK inhibitors (Mann and Jones 1996, Schwarz et al 
1995).  
Another frequent observation is that simultaneous manipulation of all the activator 
E2Fs often produce a striking phenotype. For example, combined inhibition of E2F1, 
E2F2 and E2F3 can block proliferation completely (Wu et al 2001) while 
overexpression of E2F1, E2F2 and E2F3 can transform  primary cells (Xu et al 1995).  
.  
E2F proteins have been widely implicated in carcinogenesis, mainly due to the 
significance of the RB pathway in cancer. Mutation in the RB pathway occur in nearly 
all human cancers (Sherr 1996). Deregulated activity of E2F have been found in 
different human cancers, often correlated with poor prognosis (Dimova and Dyson 
2005)  
1.5.2.4  Interaction partners of E2F 
The function of E2F proteins are aided by transcriptional coactivators. Some such as 
SRC-3 enhances E2F function by recruiting a transcriptional initiation complex to 
E2F regulated proteins (Yan et al 2006). Others may supply the necessary enzymatic 
activities to enhance E2F functions. Examples of E2F cofactors include PARP-1 
(Simbulan-Rosenthal et al 2003), HDAC1(Brehm et al 1998), CBP(Trouche et al 
1996), and C/EBPbeta and p300(Wang et al 2007). 
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Studies have shown that all E2Fs recognize the same target sequence (Lees et al 
1993). In addition, there is little variation in the sequence of various E2F elements 
(Black et al 2005). Therefore it is speculated that E2F protein has to physically 
interact with other proteins to achieve different functions. For example, the TFE3 
transcription factor has been found to be an E2F3 specific partner (Giangrande et al 
2003) and the YY transcription factor as partner for E2F2 and E2F3 (Schlisio et al 
2002). Various experiments have shown that E2F1 and E2F3 have distinct but 
overlapping roles in the activation of genes important for apoptosis, cell cycle entry 
and cell cycle progression (DeGregori et al 1997, Leone et al 1998, Shan and Lee 














1.6   Objective of studies 
We have discovered WBP2 as a tyrosine phosphorylated protein. Furthermore, WBP2 
is phosphorylated downstream of EGFR. This makes it a particularly interesting target 
to study as the EGFR pathway has been widely implicated in cancer. Furthermore, 
WBP2 is a relatively novel protein, So far it’s only known function is as a nuclear 
receptor coactivator. 
Our first objective involves characterization of WBP2 phosphorylation. In particular, 
we would like to focus on identifying the sites of WBP2 phosphorylation. 
Identification of WBP2s phosphorylation sites will enable further studies into the 
function of this phosphorylation. 
The second objective is to characterize the function of WBP2 phosphorylation. 
Tyrosine phosphorylation have been shown to be important for the function of many 
proteins. For nuclear receptor coactivators, phosphorylation have been suggested to a 
molecular switch that controls the transactivation potential and specificity of the 
proteins (Wu et al 2005). Thus we would like to elucidate the functional implication 











2 Materials and Methods 
2.1  Chemicals and reagents 
Chemicals for buffers and gels were purchased from Sigma, 1
st
 Base (Selangor Darul 
Ehsan, Malaysia) or Bio-Rad (Hercules,CA) unless otherwise stated.  Lipofectamine 
2000 and Opti-MEM were purchased from Invitrogen (Carlsbad, CA). EGF was 
purchased from Signal Aldrich (St. Louis, MO). Iressa was a kind gift from Astra 
Zeneca (Washington DC,USA). MTS assay was purchased from Promega (San Luis, 
CA). siRNAs were from Invitrogen: 
E2F1 specific siRNA: 
Sequence #1: 5’-AUGCUACGAAGGUCCUGACACGUCA-3’ 
Sequence #2: 5’-AAAGUUCUCCGAAGAGUCCACGGCU-3’ 
E2F3 specific siRNA:  
Sequence #1: 5’-UUGGAAGCGGGUUUAGGGAUAUUCC-3’ 
Sequence #2: 5’-UAAUUUCUUCUCUUCCUGACUGAGC-3’ 
WBP2 specific siRNA:5’-AGCAUCCGCUGUCCGAACUCAAUGG – 3’ 
2.2  Antibodies 
The following antibodies were purchased from BD Bioscience: EGFR monoclonal 
antibody (EGFR mAB) and anti phosphotyrosine antibody conjugated to horse radish 
peroxidase (PY20H). The following antibodies were purchased from Santa Cruz: anti-
HA, E2F1 (KH95), E2F2 (C-20), E2F3 (C-20), actin (HRP conjugated).  Anti-mouse 
and anti-rabbit agarose were obtained from Sigma Aldrich (St. Louis, MO).  
Polyclonal anti-WBP2 antibody was custom produced by NeoMPS SA (Strasbourg, 
France) (WBP2 pAb) or monoclonal antibody against WBP2 was purchased from 
Abnova (WBP2 mAb). 
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2.3  Plasmid constructs 
cDNA for WBP2 was from Origene and subcloned into pcDNA 6.2 Directional 
TOPO vector and pCEP4 (Invitrogen). pRL-TK plasmid was purchased from 
Promega. HA-E2F1, HA-E2F2 and HA-E2F3 plasmids and E2F luciferase reporter 
were kind gifts from Dr Keigo Araki(CSI, NUS). Stat reporter (M67-SIE) was a kind 
gift from Dr Lim Cheh Peng (IMCB). Wnt reporter was from Yoshiaki Ito (CSI, 
NUS). AP-1 reporter was from Richard Treismann (Cancer Research UK). NFκB 
reporter was from Vinay Tergaonkar (IMCB).  Large scale preparation of plasmids 
were performed using Purelink Hipure Filter Plasmid Maxiprep kit (Invitrogen). 
2.4  Site directed mutagenesis 
Mutations of tyrosine to phenylalanine were generated by site directed mutagenesis 
using the QuikChange mutagenesis kit (Stratagene, La-Jolla, CA). Mutations were 
verified using DNA sequencing. 
2.5  Cell culture 
MCF7 cells were cultured in RPMI-1640 with 10% FBS (Hyclone, ThermoFisher, 
Waltham, MA), 1% penicillin/streptomycin. A431, HEK-293, MDA-MB-231 cells 
were cultured in DMEM supplemented with 10% FBS, 1% penicillin/streptomycin. 
For hormone deprivation, the cells were incubated in phenol red-free RPMI-1640 
supplemented with charcoal stripped FBS. For serum starvation, cells were incubated 






2.6  Transfection 
For DNA transfection, cells were seeded at about 80-90% confluency the day before 
transfection. On the day of transfection, the medium incubating the cells was replaced 
with fresh complete growth medium, while the indicated plasmids and Lipofectamine 
2000 were diluted in Opti-MEM medium (DNA: Lipofectamine = 1ug: 2.5 uL). 
Diluted DNA and Lipofectamine were mixed together and incubated at room 
temperature for 20 minutes prior to adding to the cells. Expression was checked 48 
hours later. For siRNA transfection, reverse transfection was performed. Cells were 
transfected while they were still in suspension (i.e after tyrpsinization and prior to 
plating) 
2.7 Stable cell line establishment: 
MCF7 cells were transfected with pCEP4 vector, WT-WBP2, Y192-231E-WBP2 and 
Y192-231F-WBP2. 48 hours post transfection, cells were exposed to 250 ug/mL of 
hygromycin every 5 days for 3 weeks and screened for WBP2 expression. Selected 
clones were pooled and maintained with selection pressure. WBP2 expression was 
checked periodically. 
2.8 Cell lysis 
For cell lysis, cells were washed in PBS before lysis using non-ionic denaturing buffer 
(50 mM Tris-HCl (pH 7.5), 0.5% Triton X-100, 0.5% Igepal, 150 mM NaCl,  1 mM 
EDTA, 50 mM NaF, 1 mM Na3VO4 and protease inhibitors. Cell lysates were then 
centrifuged at 16000 rpm for 20 minutes at 4
o
C. Protein concentration was estimated 
using Bicinchoninic Acid Assay kit (Pierce Biotechnology, Rockford, IL) and 
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measuring the absorbance of 562 nM with a microplate reader (Tecan Infinite, M200, 
Tecan). 
2.9 Immunoprecipitation 
0.5 – 1 mg of cell lysates were incubated overnight with rotation at 4oC with the 
specific antibodies and antimouse or anti rabbit IgG agarose beads. The 
immunoprecipitates were spun down and washed thrice with 1 mL of NID lysis 
buffer. After washing, 2X Laemli Buffer was added to the imunoprecipitate and 
boiled at 95
 o
C for 5 minutes. The eluted proteins were then subjected to SDS-PAGE.  
2.10 Immunoblotting 
Cell lysates were resolved by SDS-PAGE using the Bio-Rad Mini-Protean II system. 
The stacking gel consists of 4% acrylamide/Bis (30:1), 0.125 M Tris-HCL (pH 6.8), 
0.1% SDS, 0.1% (w/v) ammonium persulfate and 0.01% (v/v) TEMED. The resolving 
gel was composed of 7.5-12% acrylamide/Bis (30:1), 0.375 M Tris-HCL (pH 8.8), 
0.1% SDS, 0.1% (w/v) ammonium persulfate and 0.01% (v/v) TEMED. Equal 
volume of 2x Laemmli buffer was added to the 50-100 g of cell lysates and boiled at 
95
o
C for 5 minutes before loading into the wells. The electrophoresis buffer was made 
up of 25 mM Tris, 192 mM glycine and 0.1% SDS. After the proteins were resolved, 
they are transferred from the gel to a PVDF membrane (Bio-rad) with Bio-Rad Trans-
Blot system for 1 hour at 100 V in transfer buffer (25 mM Tris, 192 mM glycine, 10% 
SDS and 20% methanol). Membranes were blocked in PBST (PBS containing 0.1% 
Tween 20) containing 1% BSA or 5% milk for 1 hour at room temperature and 
incubated with primary antibodiesovernight at 4
o
C. Membranes were then washed 
with PBST for 3 times, 5 minutes each and incubated with secondary antibody for 1 
hour.Subsequently, membranes were washed 3 times with PBST for 5 minutes each 
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before detection using the enhanced chemiluminescence (ECL) detection reagents 
(GE Healthcare, Amersham) on the X-ray film 
2.11 Proliferation assay 
Cells were seeded 96-well plates, with 4000 cells per well. 10 l of MTS reagent 
(Promega) was added to each well (containing 100 l of medium) of one plate. The 
cells were incubated at 37
o
C for 1 hour and the absorbance was determined at a 
wavelength of 492 nm using the multimode microplate reader (Tecan Infinite M200, 
Tecan). The average absorbances of the triplicates were then plotted into a graph for 
analysis.  
2.12 Luciferase assay 
Cells were plated into 24 well plates. Luciferase reporters encoding the luciferase 
reporter plasmids and Renilla luciferase (pTK-RL) were transfected into the cells. 24 
hours later, the cells were washed with PBS and lysed with passive lysis buffer 
(Promega). Measurements were performed using the Dual Luciferase reporter assay 
system (Promega). For each sample, two readings were taken, one from the firefly 
luciferase encoded by the pathway reporters and one from the Renilla luciferase 
encoded by the pTK-RL plasmid. Readings from the firefly luciferase was normalized 
using the Renilla luciferase reading.  
2.13 BrdU incorporation assay 
For BrdU incorporation assay, cells were grown in hormone freemedia. Cells were 
pulsed with BrdU (BD Pharmingen) for 30 minutes. 36 hours after pulse, cells were 




3.     Results 
3.1 Phosphorylation of WBP2 
We first discovered WBP2 as a tyrosine kinase target using a phosphoproteomics 
approach (Chen et al 2007). In the paper, To identify novel tyrosine kinases 
phosphoproteomics changes in the MCF10AT model of breast cancer progression 
were studied. The MCF10AT cells consist of immortalized cells modeled after 
normal, premalignant epithelium, low grade and high grade lesions, respectively 
(Dawson et al 1996). cells were exposed briefly to pervanadate, a tyrosine 
phosphatase inhibitor before being affinity captured using 4G10 antiphosphotyrosine 
antibodies. The captured phosphoproteins were labelled using iTRAQ reagents (Ross 
et al 2004) and subsequently analyzed using mass spectrometry to identify tyrosine 
phosphorylated proteins. Subsequently some of the proteins identified were validated 
through immunoprecipitations and probing with anti-phosphotyrosine antibodies. For 
WBP2, because WBP2 antibody was at that time unavailable, we expressed WBP2 
exogenously and found that it could be phosphorylated following EGF stimulation. 
Treatment with Iressa, an EGFR inhibitor, blocksthe phosphorylation of WBP2. Thus, 
WBP2 is potentially a target of EGFR signaling(Chen et al 2007). 
3.1.1 Phosphorylation kinetics of WBP2 
As the previous characterization of WBP2 phosphorylation was done using exogenous 
expression of WBP2, we decided to examine its phosphorylation in an endogenous 
system. A newly available WBP2 antibody was obtained from Abnova. To examine 
the tyrosine phosphorylation kinetics of WBP2 in an endogenous fashion, we used 
two different cell lines, the MDA-MB-231 cell line and A431. Both cell lines express 
high levels of EGFR and WBP2. Cells were serum starved, and stimulated with EGF 
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at a concentration of 50 ng/mL for specific time courses from 1-120 minutes. WBP2 
monoclonal antibody (mAb) was used to immunoprecipitate endogenous WBP2 and 
phosphorylation status of WBP2 was determined by probing the immunoprecipitated 
WBP2 with anti-phosphotyrosine antibody conjugated to horse radish peroxidase 
(PY20H).  
The MB-231 cell line displays “normal” EGFR kinetics, while the A431 cell line 
displays “sustained” EGFR kinetics. In normal EGFR kinetics, the receptor becomes 
auto-phosphorylated rapidly within 30 seconds following EGF stimulation but the 
phosphorylation begins to decline after 30 minutes, as the receptor is internalized and 
degraded. In sustained EGFR kinetics, the phosphorylation of the receptor remains 
detectable after several hours, due to defects in receptor downregulation (Roepstorff 
et al 2008). 
Figure 3.1 shows that in the MB-231 cells, stimulation with EGF led to rapid 
phosphorylation of EGFR, which then declines after 30 minutes. EGFR protein levels 
were constant from 0-60 minutes post stimulation and then begins to drop after 120 
minutes. Throughout this timecourse, the WBP2 levels remained constant. 
In A431 cells, stimulation with EGF too leads to rapid phosphorylation of EGFR, but 
the phosphorylation level remains high even after 120 minutes post stimulation. The 
protein levels of EGFR and WBP2 remains unchanged throughout the timecourse. 
In both cell lines, following EGF stimulation, WBP2 is phosphorylated as quickly as 
1 minute and peaks at 5 minutes (peaks are indicated with arrows). In MB-231 cell 
line, the phosphorylation of WBP2 becomes undetectable after 30 minutes, as the 
phosphorylation of EGFR begins to decline as well. In contrast, in the A431 cell line, 
the phosphorylation of WBP2 remained detectable from 30 minutes to 120 minutes 
31 
 
post phosphorylation. Throughout this time period, the EGFR phosphorylation level 
remained high. Probing with WBP2 antibody shows that similar amounts of WBP2 
was immunoprecipitated. A likely explanation is that in A431 cells, the 
dephosphorylation of WBP2 occurs at a slower pace compared to in MB-231. 
These results show that the phosphorylation of WBP2 occurs rapidly in both MB-231 
and A431 cell lines and then quickly declines. Thus, WBP2 behaves as a typical 
signaling molecule, where its signaling duration and potency have to be tightly 
regulated. WBP2 phosphorylation also correlates with EGFR phosphorylation in MB-
231 cells, in support of the hypothesis that its phosphorylation is downstream of 
EGFR activation. 
 
Figure 3.1 Tyrosine phosphorylation kinetics of WBP2. MB-231 and A431 cells 
were serum starved for 24 hours and stimulated with 50 ng/mL EGF for 0-120 
minutes. Whole cell lysates were used for immunoprecipitation and/or 




3.1.2 Determination of WBP2 phosphorylation sites 
To map WBP2 tyrosine phosphorylation sites, we used the HeLa cell lines, as the 
cells are easily amenable to transfection. There are 22 tyrosine sites in WBP2 that 
could be possibly phosphorylated. In order to narrow down the potential 
phosphorylation sites, we used various prediction softwares (Netphos 2.0, HPRD 
Phosphomotif Finder and NetphosK) to determine the likelihood of each site to be 
phosphorylated. The results of the prediction are shown in Figure 3.2A. A total of 17 
tyrosine sites were individually mutated to phenylalanine. 
As the levels of EGFR in HeLa cells were low, EGFR was co-transfected to maximize 
the effect of EGF stimulation. Mutant WBP2 were co-transfected into the cells with 
EGFR. To ensure equal amount of EGFR was co-transfected into the cells, the EGFR 
levels were probed with anti-EGFR antibodies (Figure 3.2B). To ensure that the cells 
were subjected to similar EGF stimulation conditions, the phosphorylation status of 
EGFR was also probed.  
Figure 3.2B shows that phosphorylation was significantly reduced for Y192F and 
Y231F mutant. WBP2 levels were similar throughout, indicating the reduction in 
phosphorylation was not due to lower levels of WBP2. Because there was residual 
phosphorylation in the Y192F and Y231F mutants, we mutated both sites and found 
that phosphorylation could be completely abolished in the Y192-231F double mutant 
(Figure 3.2C). We also observed that the reduction of phosphorylation in WBP2 
Y231F mutant is greater than in Y192F. Thus, although it appears that both sites are 

































Figure 3.2 Determination of WBP2 tyrosine phosphorylation sites A. Likelihood 
of phosphorylation on each of WBP2’s tyrosine sites. WBP2 tyrosine sites were 
characterized using Netphos 2.0 (likelihood of phosphorylation), HPRD 
Phosphomotif finder (kinase motifs), and NetphosK (consensus motif for EGFR 
phosphorylation). The location of tyrosines in the PPXY motifs were also indicated 
(final column). B. Tyr192 and Tyr231 were mapped to be the phosphorylation sites on 
WBP2 following EGF treatment. HeLa cells were co transfected with EGFR and 
either V5 tagged wild type or individual tyrosine (Y) to phenylalanine (F) mutant of 
WBP2. 24 hr post transfection, the cells were serum starved overnight and stimulated 
with 50 ng/mL EGF for 5 minutes. Whole cell lysates were used for 
immunoprecipitation or immunoblotting with the indicated antibodies. C. Tyr192 and 
Tyr231 double mutations were required to completely abolish the EGF induced 
tyrosine phosphorylation of WBP2. HeLa cells were cotransfected with EGFR and 
either V5 tagged wild type or individual Y192F, Y231F or double mutant (Y192-
231F) of WBP2 and phosphorylation status of WBP2 was determined as previously. 
 
3.2 Functional consequence of WBP2 phosphorylation 
3.2.1 Generation of WBP2 stable cell lines 
Tyrosine phosphorylation has been found to be important for protein functions. In 
order to characterize the function of WBP2 phosphorylation on cellular processes, we 
decided to create cells stably expressing WBP2. To mimic the phosphorylation of 
WBP2, we mutated Y192 and Y231 to glutamic acid (E) while for the 
phosphorylation defective mutant, the Y192-231F mutant was used. MCF7 was  
chosen for stable expression as it expresses relatively low amounts of WBP2 (Figure 
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3.3A). WBP2 stable cell lines were generated using hygromycin selection. To avoid 
clonal variations, clones were pooled. Expression of WBP2 was then probed (Figure 
3.3B). The expression level of the WBP2 protein is similar across the cell lines. The 
Y192-231E-WBP2 migrated slower compared to WT-WBP2. This may be due to the 
more polar nature of the protein following the Y to E mutation. On the other hand, the 












Figure 3.3 Generation of MCF7 cells stably expressing WBP2 and its mutants. A. 
Expression of WBP2 in breast cancer cell lines. Cell lysates were generated from a 
panel of breast cancer cell lines. WBP2 expression was probed using WBP2 antibody 
and actin levels were probed as loading control. B. Generation of WBP2 stable cell 
line. Cell lysates from hygromycin resistant pooled MCF7 cell clones were prepared 




3.2.2 Effect of WBP2 phosphorylation on proliferation 
We hypothesize that WBP2 phosphorylation may play a role in modulating cell 
processes such as cell proliferation. To check for the effect of WBP2 phosphorylation 
on proliferation, we performed MTS assay on the MCF7 cells stably expressing WT-
WBP2, Y192-231F WBP2 and Y192-231E WBP2.  Since one of the established 
function of WBP2 is as a coactivator for estrogen receptor, we also decided to see if 
WBP2 overexpression may also alter the cells proliferative response to estradiol (E2). 
As can be seen in Figure 3.4, in the cells overexpressing WT-WBP2, the proliferation 
was higher compared to control cells overexpressing the vector. The highest 
proliferation was seen in cells expressingY192-231E-WBP2. The proliferation was 
enhanced by the addition of E2 in WT-WBP2 expressing cells, but in the Y192-231E-
WBP2 expressing cells, the proliferation rate is similar with or without E2 
stimulation. In the Y192-231F-WBP2 expressing cells, the proliferation rate was 
lower compared to WT-WBP2 expressing cells. The addition of E2 did not enhance 
the proliferation. 
Theseresults imply that the phosphorylation mimic of WBP2 could drive proliferation 
without depending on hormone stimulation. The phosphorylation sites were also 
important for both estrogen dependent and estrogen independent proliferation, as 
Y192-231F-WBP2 expressing cellsis unresponsive to estrogen and proliferates slower 
than the WT-WBP2 expressing cells.  
The observation that the expression of WBP2 can stimulate the proliferation of MCF7 
cells independently of hormone suggests that WBP2 may also have other functions 




Figure 3.4 Cell proliferation of MCF7 cells stably expressing WBP2 . MCF7 cells 
stably expressing vector, WBP2 and its mutants were plated in 96 well plates in 
charcoal stripped media. Cell proliferation was measured using MTS assay for 4 days. 
Cells were stimulated with E2 daily where indicated. The data was representative of 3 
independent experiments with similar results. * denotes p-value <0.01 compared to 
vector expressing cells. 
 
 
3.3 Activation of the E2F pathway in cells expressing Y192-231E-WBP2 
3.3.1 E2F luciferase reporter assay on MCF7 stable cell lines 
In order to check for a possible mechanism by which WBP2 (Y192-231E) stimulates 
proliferation independently of hormone, we screened through a number of luciferase 
reporter of transcription factors that are usually involved in control of cell 
proliferation. The luciferase reporters were transfected into the MCF7 stable cell lines 
to measure the pathway activity in the cells. The results of the screen are shown in 
Figure 3.5. One of the reporters that we tested was the E2F luciferase reporter. As can 






WBP2expressing cells (~3 fold over vector). There is little difference between cells 
















Figure 3.5 Reporter luciferase assays. MCF7 cells stably expressing vector, WBP2 
and its mutants, were transfected with the reporter luciferase plasmids for NFkB, Wnt, 
AP-1, Stat3/5, and E2F together with Renilla luciferase. Readings were normalized 
using Renilla luciferase readings. Data is expressed as fold induction over the level 
observed with the vector expressing cell. Data is representative of 3 independent 
experiments with similar results. * denotes p value <0.05 and ** denotes p value 
<0.01 compared to vector readings. 
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For the other reporter system, NFkB and Wnt luciferase reporter also displayed higher 
activity in cells expressing Y192-231E-WBP2. The Stat 3/5 reporter and AP-1 
reporter did not display elevated activity. As E2F activity was elevated, and E2F 
pathway plays a major role in control of cell proliferation, we decided to focus on 
studying the possible involvement of E2F pathway in phospho-WBP2 mediated cell 
proliferation. 
3.3.2 Elevation of E2F proteins in Y192-231E-WBP2 expressing cells  
As E2F luciferase activity was increased, we asked the question whether E2F proteins 
too were upregulated. Enhanced levels of E2F proteins have been found to lead to 
higher E2F activity. (DeGregori 2002).To check for E2F protein levels in the MCF7 
stable cells, we obtained the cell lysates from the MCF7 stable cells and performed 
Western Blotting using E2F antibodies. As seen in Figure3.6A, the E2F1-3 proteins 
were elevated in the MCF7 (Y192-231E). Probing of actin showed consistent loading 
of samples between different lanes.The elevation of E2F proteins only in the Y192-
231E-WBP2 expressing cells is consistent with the results of the E2F luciferase 
reporter assay, where the E2F activity is highest in the Y192-231E-WBP2 cells.  
It has also been reported that the loss of Rb is a possible mechanism by which E2F 
activity is increased (Brehm et al 1998). Under normal conditions, Rb is bound to the 
activator E2Fs and prevent them from binding to E2F response elements.  The loss of 
Rb frees the activator E2Fs to bind to E2F response elements, leading to higher E2F 
activity. To check if the loss of Rb could account for the increased E2F activity, we 
checked for the levels of Rb across the MCF7 stable cell line. Our results show that 
the levels of Rb remains constant. 
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To check whether the increase in the E2F proteins in MCF7 (Y192-231E) are actively 
regulated by WBP2, we reduced WBP2 level  using siRNA. As shown in Figure3.6B, 
the WBP2 siRNA successfully knocked down WBP2 to a low level whereas the non-
specific siRNA did not affect WBP2 level. Following WBP2 knockdown, the levels 


















Figure 3.6 E2F proteins in MCF7 cells stably expressing vector, WBP2 and its 
mutants. A. Cell lysates from the MCF7 cells stably expressing vector, WBP2 and its 
mutants were prepared and Western blotting was performed using the indicated 
antibodies. B. Reversal of E2F elevation following WBP2 knockdown. MCF7 cells 
expressing Y192-231E-WBP2 were subjected to non-specific siRNA or WBP2 
siRNA. Cell lysates were prepared and probed using the indicated antibodies.  
 
3.3.3 Possible interaction between WBP2 and E2F proteins 
One of the mechanism by which transcriptional coregulators increase the 
transactivation potential of transcription factors is through direct interaction (Lonard 
and O'Malley B 2007). Therefore we tested if WBP2 could interact directly with the 
E2F transcription factors to mediate E2F functions. As the higher E2F activity was 
only seen in cells expressing Y192-231E-WBP2, we hypothesize that this interaction 
will only occur when WBP2 is tyrosine phosphorylated. Therefore we transfected 
HA-tagged E2F1, E2F2 and E2F3 into Y192-231E-WBP2 expressing MCF7. The 
transfection efficiency was checked by probing with antibodies against HA tag 
(Figure 3.7A). We co-immunoprecipitated WBP2 from the WBP2 Y192-231E 
expressing cells and probe for HA-E2F1, HA-E2F2 and HA-E2F3, and did the 
reciprocal experiments. No interaction between WBP2 and E2F1, E2F2 and E2F3 was 
detected (Figure 3.7B). Therefore, we conclude that WBP2 may not interact with 






















Figure 3.7: Co-immunoprecipitation between WBP2 and E2F1, E2F2 and E2F3. 
A. Plasmids encoding HA-E2F1, HA-E2F2 and HA-E2F3 were transfected into 
MCF7 cells stably expressing Y192-231E-WBP2. Transfection efficiency of HA-
tagged E2F proteins were monitored by immunoblotting with anti-HA antibody. B. 






3.3.4  Cell cycle analysis of MCF7 stable cell lines 
One of the most widely studied function of the E2F pathway is the induction of cell 
cycle entry (Leone et al 1998, Shan and Lee 1994). Entry into the cell cycle is 
characterized by synthesis of new DNA, in preparation for cell replication. As the 
Y192-231E-WBP2 expressing MCF7 shows elevated E2F activity, we hypothesize 
that the cells should also display increased DNA synthesis.   
In order to check the level of newly synthesized DNA in the stable cell lines, we 
performed BrdU incorporation assay. BrdU, a thymidine analog, is incorporated into 
newly synthesized DNA, which is then detected using anti BrdU antibody. As shown 
in Figure 3.8A and Figure 3.8B, the BrdU incorporation was highest in cells 
expressing Y192-231E-WBP2. Cells expressing the WBP2 WT and WBP2 (Y192-
231F) also showed elevated BrdU incorporation, although not as high as that in 
WBP2 (Y192-231E) expressing cells.  The results suggest that WBP2 overexpression 
may promote cell cycle entry, and phosphorylation of WBP2 enhances its ability to 



























Figure 3.8 BrdU analysis of MCF7 cells stably expressing vector, WBP2 and its 
mutants. A. Cells were grown in charcoal stripped RPMI media for 2 days. Cells 
were pulsed with BrdU for 30 minutes. 36 hours later, the cells were prepared using 
the protocol described in BrdU Pharmingen kit. 2 parameter analysis (Y-axis: BrdU, 
green; X-axis: DNA, red) was performed using Beckman Coulter Flow Cytometer. B. 
Data shown is representative of two independent experiments with similar results. * 






3.3.5 Role of E2F1 and E2F3 in increased E2F activity in MCF7 cells expressing 
Y192-231E-WBP2 
As E2F1, E2F2 and E2F3 were found to be increased in Y192-231E-WBP2 
expressing cells, we hypothesize that this may be a mechanism by which E2F activity 
is increased. To test this hypothesis, we chose E2F1 and E2F3 for further 
characterization, as they are relatively more well studied compared to E2F2 (Black et 
al 2005, Kong et al 2007). We knocked down E2F1 and E2F3 to see if the E2F 
luciferase activity in the Y192-231E-WBP2 expressing cells could be reduced. For 
comparison, we also knocked down WBP2. WBP2 knockdown leads to reduced 
protein levels of E2F1 and E2F3 (Figure 3.9A), in agreement with earlier results. Two 
different siRNAs were used for E2F1 knockdown and E2F3 knockdown respectively. 
As seen in Figure 3.9A, E2F1 and E2F3 protein levels were effectively knocked down 
by their respective siRNAs.  
Figure 3.9B shows that the E2F luciferase activity was reduced by approximately50% 
compared to control upon WBP2 knockdown. Knockdown of E2F1 reduced the E2F 
luciferase activity to levels lower than WBP2 knockdown (approximately 40%), 
whereas E2F3 knockdown reduces E2F luciferase activityto approximately75% 
compared to control.   
The results show that E2F1 and E2F3 elevation may play a role in the increase of E2F 





















Figure 3.9 Effect of knockdown of WBP2, E2F1 and E2F3 on E2F luciferase 
reporter assay. A. WBP2, E2F1 and E2F3 were knocked down in MCF7 stably 
expressing WBP2 (Y192-231E) with respective siRNAs. Protein levels were probed 
with the indicated antibodies. B. Luciferase assay was performed as described 
previously. Data shown is representative of the average of 3 independent experiments. 






3.3.6 Role of E2F1 and E2F3 in increased cell cycle entry in MCF7 cells 
expressing Y192-231E-WBP2 
To show that the E2F pathway is involved in increased DNA synthesis shown 
previously, the MCF7 cells stably expressing WBP2 (Y192-231E) were analyzed for 
BrdU incorporation following siRNA knockdown on WBP2, E2F1 and E2F3.Figure 
3.10 shows that in cells where the WBP2 has been knocked down, the percentage of 
BrdU positive cells were reduced to around 70%. E2F1 knockdown reduced the BrdU 
positive cells to around 40-50% whereas E2F3 knockdown reduced the BrdU positive 
cells to around 40-60. The results show that E2F1 and E2F3 may account for 












Figure 3.10: Effect of knockdown of WBP2, E2F1 and E2F3 on cell cycle entry in 
MCF7 stably expressing WBP2 (Y192-231E). MCF7 cells stably expressing WBP2 
(Y192-231E) grown in charcoal stripped RPMI media were subjected to either WBP2, 
E2F1 and E2F3 siRNAs and analyzed using BrdU incorporation assay. Bar chart 
shows the percentages of BrdU positive cell compared to cells subjected to control 
siRNA. Data shown is representative of two independent experiments with similar 
results. * denotes p-value <0.05.  
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3.3.7 Role of E2F1 and E2F3 in increased cell proliferation in MCF7 cells 
expressing Y192-231E-WBP2 
The E2F pathway have been linked to control of cell proliferation(Wu et al 2001). To 
test for the effect of E2F pathway knockdown on the proliferation of MCF7 cells 
stably expressing Y192-231E-WBP2, we again performed WBP2, E2F1 and E2F3 
knockdown. 
Figure 3.11B shows the percentages of cell proliferation of Y192-231E-WBP2 
expressing cells compared to non-specific siRNA control after 3 days. Following 
WBP2, E2F1 and E2F3 knockdown, the cell proliferation was reduced in Y192-231E-
WBP2 expressing MCF7 cells. E2F1 and WBP2 siRNAs were able to reduce 
proliferation to around 60% while E2F3 siRNA was able to reduce cell proliferation 
to around 70%.  
The results are consistent with the results from the luciferase and BrdU incorporation 
assay. E2F1 and E2F3 appear to play important roles in the increased E2F activity, 
























Figure 3.11: Effect of knockdown of WBP2, E2F1 and E2F3 on cell proliferation 
in MCF7 cells stably expressing WBP2 (Y192-231E) cells. A. Cells grown in 
charcoal stripped RPMI media were subjected to siRNA against WBP2, E2F1 and 
E2F3. Knockdown efficiency was checked by probing with indicated antibodies. B. 
Cells were counted and 5000 cells were seeded per well in 96 well plate in RPMI 
supplemented with charcoal stripped medium. MTS assay was performed on day 3, 
and readings obtained were expressed as percentages of the proliferation of cells 
subjected to non-specific siRNAs. Data shown is representative of 3 independent 





4.  Discussion 
4.1   Phosphorylation of WBP2 
By characterizing the phosphorylation kinetics of WBP2, we found that WBP2 
phosphorylation occurs rapidly following EGF stimulation and quickly declines.  The 
rapid phosphorylation and dephosphorylation of WBP2 is similar to reports of other 
proteins that are targets of tyrosine kinases(Neumann-Giesen et al 2007, Van Itallie et 
al 1995).Tyrosine phosphorylation is usually a consequence of rapid activation of 
growth factor receptor tyrosine kinases and cytoplasmic protein tyrosine kinases upon 
ligand stimulation(Yarden and Sliwkowski 2001). It may be likely that tyrosine 
phosphorylation ofWBP2 is an early rate limiting modification that influences 
phosphorylation and posttranslational modifications at other sites. 
The identity of the phosphatase responsible for dephosphorylating WBP2 is currently 
unknown and will be interesting for future studies.To our knowledge, WBP-2 is only 
the second steroid receptor coactivator after SRC-3 that could undergo tyrosine 
phosphorylation. Like WBP2, SRC-3 is also tyrosine phosphorylated upon EGF 
stimulation(Oh et al 2008).  
Using the prediction softwares HPRD Phosphomotif finder (Amanchy et al 2007), 
Netphos 2.0 (Blom et al 1999), and NetphosK 1.0 (Blom et al 2004), we narrowed 
down the possible phosphorylation sites to 17 based on the likelihood of 
phosphorylation, whether they contain consensus sequences for various tyrosine 
kinases and phosphatases, the likelihood of being phosphorylated by EGFR and 
whether the sites were within the PY motifs of WBP2. 
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Mutations of WBP2 tyrosine sites lead to the identification of Y192 and Y231 as 
WBP2 phosphorylation sites. Interestingly, Y192 is predicted to be phosphorylated by 
Netphos 2.0, and has the consensus phosphorylation motif for EGFR. Y231 too was 
predicted to be phosphorylated by Netphos 2.0, although it does not contain the 
consensus for EGFR.  
Y192 and Y231 are embedded within the polyproline rich domain of WBP2 that 
consist of three highly conserved PY motifs. However, the sites are not located within 
the PY motifs themselves. PY motif mediates protein-protein interactions and is 
present in many transcriptionfactors and coactivators, including c-Jun(Baichwal and 
Tjian 1990), AP-2 (Williams and Tjian 1991), C/EBPα(Nerlov and Ziff 1994). It is 
conceivable that thephosphorylation of WBP2 functions to control itsPY motif 
mediated interactions.  
 
4.2 Functional Consequence of WBP2 phosphorylation 
Using MCF7 stably expressing WBP2, we found that WBP2 could drive estrogen 
dependent and estrogen independent cell proliferation and the phosphorylation mimic 
of WBP2 confers hormone independent growth.The ability to promote hormone 
independent cell proliferation appears to be similar to what have been reported for 
SRC-3 (Louie et al 2004).  
As WBP2 is able to drive proliferation independently of hormone, we speculate that 
WBP2 may also participate in signaling pathways other than those involving steroid 
receptors. It has been well established that steroid receptor coactivators may also 
function as coactivators for non-steroid receptor signaling pathways (O'Malley 2007) . 
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By testing reporters for various signaling pathways, we found that WBP2 could 
enhance E2F reporter activity. The increase of 3 fold seen in the Y192-231E-WBP2 
expressing cells is in line what was reported for SRC-3 activation for E2F luciferase 
reporter (Louie et al 2004). The other reporters Stat, NFκB, AP-1 and Wnt (Brown 
2001, Garcia et al 2001, Karin and Lin 2002, Shen et al 2008) were chosen because 
they have been reported to play roles in breast cancer proliferation. Positive results 
were seen for Wnt reporter and NFκB while Stats and AP-1 results were negative. 
Although there remains work to be done, the positive results for some of the reporter 
assays show that WBP2 may potentially regulate a large number of transcription 
factors. 
One of the mechanisms by which E2F activity may be upregulated by WBP2 is 
through direct interaction between WBP2 and the E2F proteins. This has been shown 
to be true for the SRC-3 mediated elevation of E2F1 activity.SRC-3 coactivation of 
E2F1 involves its recruitment to promoters of genes regulated by E2F1, and direct 
interaction between E2F1 and SRC-3(Louie et al 2004). However, the effect of SRC-3 
tyrosine phosphorylation on E2F coactivation has not been reported. So far, we have 
not been able to show any interaction between E2F1 and WBP2. The interaction may 
occur in a temporal manner and therefore difficult to detect. 
We found that the levels of E2F1, E2F2 and E2F3 are elevated in MCF7 cells 
expressing Y192-231E-WBP2. E2F1, E2F2 and E2F3 can all function to enhance 
transcription on E2F response elements(Lees et al 1993). It is believed that higher 
levels of E2F proteins in cells can tip the balance towards higher E2F activity 
(DeGregori et al 1997). The levels of E2F1, E2F2 and E2F3 have been found to be 
elevated in cancer cells compared to normal cells (Johnson and Schneider-Broussard 
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1998). Thus, the increase of E2F protein levels may be a mechanism of E2F activity 
elevation in the cells expressing phospho-mimic WBP2. 
Cells cultured over long periods of time may undergo genetic changes. To rule out the 
possibility of E2F elevation being an artifact, we performed knockdown on WBP2 to 
show that the increase in E2F proteins is due to active regulation by WBP2. As E2F 
protein levels in MCF7 Y192-231E) appear to be reversed following WBP2 
knockdown, WBP2 may actively regulate the levels of E2F proteins through control 
of their transcription.  
One of the primary effects of E2F pathway elevation is increased cell cycle entry, 
which results in higher DNA synthesis(Leone et al 1998, Shan and Lee 1994). Cell 
proliferation assay such as the MTS assay may be confounded by induction of 
antiapoptotic program in the cells. In a stable cell system, increased proliferation may 
also be attributed to induction of the anti apoptotic program, leading to less cell death. 
To rule out this possibility, we performed BrdU assay on the stable cell lines as a 
direct measurement of new DNA synthesis. The immunofluorescent staining of 
incorporated bromodeoxyuridine (BrdU) and flow cytometric analysis provide a high 
resolution technique to determine the frequency and nature of individual cells that 
have synthesized DNA. As our results show that DNA synthesis is enhanced in the 
MCF7 (Y192-231E), it lends credence to our hypothesis that the E2F pathway 
enhancement leads to higher DNA synthesis. However, DNA synthesis was also 
found to be increased in cells stably expressing WT-WBP2 and Y192-231F-WBP2, 
despite the observation that E2F activity was not elevated in these cells. Thus E2F 
activity cannot account for these increases in DNA synthesis. WBP2 may likely 




4.3 Mechanism of WBP2 upregulation of E2F activity 
Our results so far indicate that phosphorylated WBP2 may upregulate E2F activity 
through increases in E2F proteins.  This results in increased cell cycle entry, and cell 
proliferation. The exact mechanism of how this occurs is unclear. WBP2 may cause 
an upregulation of another transcription factor which controls the transcription of E2F 
proteins. The E2F proteins are known to be subjected to regulation by multiple 
transcription factors, among others c-myc (Fernandez et al 2003, Leone et al 2001), 
ER (Stender et al 2007), and also E2F proteins themselves(Araki et al 2003). In 
addition, the activity of E2F proteins are also tightly regulated along with the cell 
cycle(Johnson and Schneider-Broussard 1998). Although we have shown that 
knockdown of E2F proteins in Y192-231E-WBP2 expressing cells reduces cell cycle 
entry, it does not preclude the possibility that the increases in E2F proteins are 
themselves a consequence of increased cell cycle progression, which is accompanied 
by increased transcription activity of many cell cycle related transcription factors 
which may regulate E2F protein levels.  
The function of E2F transcription factors are mediated by the downstream proteins 
that they regulate. E2F proteins regulate a large number of cell cycle related proteins, 
as well as proteins related to mitosis, and DNA replication (Black et al 2005). We 
have not looked into details at the proteins that are regulated by E2F proteins. 
Identifying the functional proteins downstream of the E2F pathway will help in 
understanding in detail how WBP2 causes increased cell proliferation. 
Recently it has been reported that WBP2 may be important for the transformation 
ability of TAZ(Chan et al 2010). TAZ is WW domain containing protein that has been 
shown to be elevated in breast cancer. Overexpression of TAZ in normal MCF10A 
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cells induced morphological changes characteristic of cell transformation and 
enhanced cell migration and invasion(Chan et al 2008).  TAZ mediates cell 
transformation through the activation of the TEAD transcription factors(Zhang et al 
2009).Interestingly, it was reported that the WW domain mediated interaction with 
WBP2 promotes the transforming ability of TAZ. The interaction of WBP2 and TAZ 
occurs through the second PPXY motif of WBP2 (a.a 197-200)(Chan et al 2010).  As 
the phosphoyrylation of WBP2 occurs at Y192 and Y231, it is highly likely that the 
interaction of WBP2 and TAZ may be regulated by WBP2 phosphorylation.  It would 
be interesting to also explore the possibility that TAZ may be important for the 















5  Conclusion 
 
In conclusion, we have characterized WBP2 phosphorylation kinetics and determined 
its phosphorylation sites. Phosphorylation of WBP2 in the cell leads to enhanced cell 
proliferation, even in the absence of hormones. Through screening of reporter assays, 
we find that the E2F pathway is elevated in phospho-WBP2 expressing cells. We have 
determined that one of the mechanisms of E2F pathway activation in phospho-WBP2 
expressing cellsis through increases in levels of E2F proteins. Knockdown E2F1 and 
E2F3 leads to partial reversal of increased cell cycle entry and proliferation in 
phospho-WBP2 expressing cells.  
Tyrosine phosphorylation of WBP2 may function as an on off switch that controls its 
function. Our study adds to better understanding of how WBP2 function is regulated, 
and describes E2F as one of the pathways that may mediate WBP2 function. The 
exact mechanism of how phosphorylation of WBP2 leads to increased E2F activity is 










6.  Future Work 
There remains a large amount of work to be done to fully characterize the 
tyrosinephosphorylation of WBP2 with respect to E2F pathway. In particular, the 
mechanism of WBP2 mediated increases in the E2F pathway will be of particular 
interest. Does WBP2 interact with another transcription factor which regulates E2F 
activity? Or does WBP2 stabilize the E2F proteins? The elucidation of E2F target 
genes that are regulated by WBP2 will be another interesting area of study. If WBP2 
is indeed a coactivator for E2F, it should be able to interact with E2F protein members 
as well as being directly recruited to some of these genes that are regulated by E2F. 
As both E2F1 and E2F3 appears to play a role in phospho-WBP2 mediated 
proliferation, it would be interesting to see if a combined knockdown would lead to 
greater decrease of proliferation. 
The function of WBP2 is almost certainly mediated through interaction with protein 
partners. Identification of these partners through protein interaction studies will 
provide a better insight and mechanistic understanding into the function of WBP2. 
Additionally, these protein interactions may be mediated by WBP2 tyrosine 
phosphorylation, which will be another interesting area of study. 
WBP2 appears to be capable of regulatingvarious cellular pathways. In our reporter 
assays, we have shown that WBP2 is able to transactivate the NFκB and Wnt 
pathway.Both pathways have been linked to cancer and is therefore interesting to 
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